newsfilter
← Latest News
PR Newswire·

Mirati Therapeutics Provides Update on Regulatory Review in the European Union of KRAZATI (adagrasib) for the Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) with a KRAS G12C Mutation

SAN DIEGO and ZUG, Switzerland, July 21, 2023 /PRNewswire/ -- Mirati Therapeutics, Inc.® (NASDAQ:MRTX), a commercial stage biotechnology company, today announced the European Medicine Agency's (EMA) Committee